Risdon Pharma

Risdon Pharma is a drug discovery company focused on developing novel small molecule inhibitors of deubiquitinating enzymes (DUBs) for the treatment of cancer. The company's lead program targets Ubiquitin-specific protease 7 (USP7), an enzyme that plays a critical role in regulating the stability of key tumor suppressors and oncogenes. By selectively inhibiting USP7, Risdon Pharma's candidates aim to induce tumor cell death and overcome resistance to existing therapies. Based in the United Kingdom, the company utilizes a structure-based drug design approach to advance its pipeline of precision oncology therapeutics. The founding team brings extensive experience in medicinal chemistry and translational biology from the pharmaceutical industry.